List view / Grid view

Research & Development (R&D)

 

article

Future of oral small molecule drugs – addressing potential in multiple sclerosis

3 October 2024 | By ,

Advances in selectivity, safety, and patient convenience, oral small molecule drugs continue to be a key focus in drug development. Here, Dr Andreas Muehler and Daniel Vitt, PhD, the co-founders of Immunic Therapeutics, discuss the potential of Vidofludimus calcium as a breakthrough treatment for autoimmune diseases.